Inhibition of the Class II HMG-CoA reductase of Pseudomonas mevalonii

被引:15
|
作者
Hedl, M [1 ]
Rodwell, VW [1 ]
机构
[1] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA
关键词
HMG-CoA reductase; Class IIHMG-CoA reductase; Pseudomonas mevalonii; isoprenoid biosynthesis; statin drug; Lovastatin;
D O I
10.1110/ps.03597504
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There are two structural classes of HMG-CoA reductase, the third enzyme of the mevalonate pathway of isopentenyl diphosphate biosynthesis-the Class I enzymes of eukaryotes and the Class II enzymes of certain eubacteria. Structural requirements for ligand binding to the Class II HMG-CoA reductase of Pseudomonas mevalonii were investigated. For conversion of mevalonate to HMG-CoA the -CH3, -OH, and -CH2COO- groups on carbon 3 of mevalonate were essential for ligand recognition. The statin drug Lovastatin inhibited both the conversion of HMG-CoA to mevalonate, and the reverse of this reaction. Inhibition was competitive with respect to HMG-CoA or mevalonate and noncompetitive with respect to NADH or NAD(+). K-i values were millimolar. The over 10(4)-fold difference in statin K-i values that distinguishes the two classes of HMG-CoA reductase may result from differences in the specific contacts between the statin and residues present in the Class I enzymes but lacking in a Class II HMG-CoA reductase.
引用
收藏
页码:1693 / 1697
页数:5
相关论文
共 50 条
  • [1] QSAR Regression Models for Predicting HMG-CoA Reductase Inhibition
    Ancuceanu, Robert
    Popovici, Patriciu Constantin
    Draganescu, Doina
    Busnatu, Stefan
    Lascu, Beatrice Elena
    Dinu, Mihaela
    PHARMACEUTICALS, 2024, 17 (11)
  • [2] Functional Implications of HMG-CoA Reductase Inhibition on Glucose Metabolism
    Han, Ki Hoon
    KOREAN CIRCULATION JOURNAL, 2018, 48 (11) : 951 - 963
  • [3] The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation
    Gelosa, Paolo
    Cimino, Mauro
    Pignieri, Alice
    Tremoli, Elena
    Guerrini, Uliano
    Sironi, Luigi
    VASCULAR HEALTH AND RISK MANAGEMENT, 2007, 3 (05) : 567 - 577
  • [4] SYNTHESES OF HMG-COA REDUCTASE INHIBITORS
    MIYACHI, N
    SUZUKI, M
    OHARA, Y
    HIYAMA, T
    JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN, 1995, 53 (03) : 186 - 196
  • [5] HMG-CoA Reductase Inhibitors and Myotoxicity
    Memduh Ucar
    Tom Mjörndal
    Rune Dahlqvist
    Drug Safety, 2000, 22 : 441 - 457
  • [6] Statin inhibition of HMG-CoA reductase: a 3-dimensional view
    Istvan, E
    ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (01) : 3 - 8
  • [7] COMPARISON OF DIFFERENT HMG-COA REDUCTASE INHIBITORS
    DITSCHUNEIT, HH
    KUHN, K
    DITSCHUNEIT, H
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 : S27 - S32
  • [8] HMG-CoA reductase inhibitors in atherosclerosis.
    Buckley, BM
    INSULIN RESISTANCE, METABOLIC DISEASES AND DIABETIC COMPLICATIONS, 1999, 1177 : 219 - 224
  • [9] Regulation of HMG-CoA reductase in mammals and yeast
    Burg, John S.
    Espenshade, Peter J.
    PROGRESS IN LIPID RESEARCH, 2011, 50 (04) : 403 - 410
  • [10] Comparative Tolerability of the HMG-CoA Reductase Inhibitors
    John A. Farmer
    Guillermo Torre-Amione
    Drug Safety, 2000, 23 : 197 - 213